Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice.

The SCID mouse represents a valuable tool for assessing growth characteristics and drug sensitivity of human leukemic cells. We have examined differences in the engraftment patterns in SCID mice of primary human leukemic cells isolated from children (< 21 years old) with either t(1;19)+/E2A-PBX1+ or t(9;22)+/BCR-ABL+ acute lymphoblastic leukemia. Leukemic cells from 13/24 t(1;19)+/E2A-PBX1+ patients caused overt leukemia in SCID mice. Macroscopic lesions were evident in 6/13 cases, with multiple sites involved in some mice: hepatomegaly,(3) splenomegaly(4), thymic enlargement; liver tumors(1), kidney tumors(1), abdominal tumors(1). Microscopic lesions in SCID mouse organs were present in all 13 cases and involved the bone marrow, brain, heart, gut, liver, kidney, lung, ovary, pancreas, skeletal muscle, spleen, and thymus. Leukemic cells from 5/20 t(9;22)+/BCR-ABL+ patients caused overt leukemia in SCID mice. Notably, macroscopic lesions (splenomegaly; leukemic bones; hepatic tumors) were observed in only 1 case. In all 5 cases, microscopic lesions were found in the mouse bone marrow. Additional microscopic lesions were restricted to skeletal muscle, spleen, and mesentery (1 case) or thymus (1 case). These findings differ markedly from those of t(1;19)+/E2A-PBX1+ leukemic cells due to the lack of involvement of major organs such as liver, pancreas, kidney, skin, or brain. These data illustrate the biological heterogeneity of childhood ALL and suggest that the differential risks associated with t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL ALL might arise from unique engraftment and proliferation capabilities of the respective leukemic cell populations.

[1]  N. Heerema,et al.  Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies , 1998, Cancer.

[2]  H. Sather,et al.  Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Heerema,et al.  Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  I. Lewis,et al.  Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. , 1998, Blood.

[5]  W. Evans,et al.  In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  N. Heerema,et al.  Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative. , 1997, Leukemia & lymphoma.

[7]  H. Sather,et al.  Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.

[8]  J. Dick,et al.  Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. , 1996, Blood.

[9]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[10]  N. Tumer,et al.  In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. , 1995, Blood.

[11]  J. Jin,et al.  In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. , 1995, Blood.

[12]  A. Bleyer,et al.  Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. , 1995, Blood.

[13]  F. Behm,et al.  Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Downing,et al.  Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1994, Blood.

[15]  N. Heerema,et al.  Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. , 1994, Blood.

[16]  J. Downing,et al.  Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1993, Blood.

[17]  S. Raimondi.  Current Status of Cytogenetic Research in Childhood Acute Lymphoblastic Leukemia , 1993 .

[18]  H. Sather,et al.  Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Irvin,et al.  In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. , 1993, Leukemia.

[20]  D. Arthur,et al.  In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1992, Blood.

[21]  S. Kamel‐Reid,et al.  Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. , 1991, Blood.

[22]  J. Dick,et al.  Transplantation of Normal and Leukemic Human Bone Marrow into Immune‐Deficient Mice: Development of Animal Models for Human Hematopoiesis , 1991, Immunological reviews.

[23]  M. Cleary,et al.  The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. , 1991, Blood.

[24]  Jonathan J. Shuster,et al.  Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study , 1990 .

[25]  Michael L. Cleary,et al.  Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor , 1990, Cell.

[26]  J. Dick,et al.  A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. , 1989, Science.

[27]  C. Bloomfield,et al.  Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. , 1989, Cancer genetics and cytogenetics.

[28]  J. Rowley,et al.  Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Ledbetter,et al.  Immunobiologic differences between normal and leukemic human B-cell precursors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  I. Weissman,et al.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. , 1988, Science.

[31]  Donald E. Mosier,et al.  Transfer of a functional human immune system to mice with severe combined immunodeficiency , 1988, Nature.

[32]  N. Heisterkamp,et al.  Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia , 1987, Cell.

[33]  O. Witte,et al.  Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. , 1987, Science.

[34]  Y. Kaneko,et al.  Balanced and unbalanced 1;19 translocation‐associated acute lymphoblastic leukemias , 1986, Cancer.

[35]  A. Bleyer,et al.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Canaani,et al.  ALTERED TRANSCRIPTION OF AN ONCOGENE IN CHRONIC MYELOID LEUKAEMIA , 1984, The Lancet.

[37]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[38]  N. Breslow,et al.  Analysis of Survival Data under the Proportional Hazards Model , 1975 .

[39]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[40]  F. Uckun,et al.  Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. , 1989, Blood.